Julie Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology and keynote speaker at Patient-Centered Oncology Care 2015, explains the importance of the meeting and how patients benefit when a diverse set of stakeholders come together in one room.
Julie Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology and keynote speaker at Patient-Centered Oncology Care 2015, explains the importance of the meeting and how patients benefit when a diverse set of stakeholders come together in one room.
Transcript (slightly modified for readability)
The American Journal of Managed Care's Patient-Centered Oncology meeting brings together a mix of healthcare stakeholders—what impact does this meeting have on healthcare?
These types of meetings are really important. A lot of times we stay in our individual little silos and don't get together and talk, so having all the stakeholders together who are involved in this process, such as with this meeting, I think will be very important. To try to get everybody in one room, have a discussion, talk about the individual situations, and how can we try to come to a solution to all work together to improve cancer care and to make it a value proposition for the patient.
How do patients benefit when such a diverse set of stakeholders gets together at a meeting like Patient-Centered Oncology Care?
I think a lot of times the physicians don't know what some of the drugs cost or the treatments cost, so trying to make sure we get everyone together in the same room and try to understand the information and to make sure everyone is collaborating and discussing things together is very important. So whenever we do that the patient is the one who benefits because we can clarify this and be sure we're using the research in the right way and get the information to the patient, what is most valuable to that individual patient.
See the full agenda and register now to save your seat: www.ajmc.com/meetings/pcoc15
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More